CN107614530A - 用于多发性骨髓瘤（mm）的治疗 - Google Patents

用于多发性骨髓瘤（mm）的治疗 Download PDF

Info

Publication number
CN107614530A
CN107614530A CN201680027238.0A CN201680027238A CN107614530A CN 107614530 A CN107614530 A CN 107614530A CN 201680027238 A CN201680027238 A CN 201680027238A CN 107614530 A CN107614530 A CN 107614530A
Authority
CN
China
Prior art keywords
antibody
seq
sequence
ser
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680027238.0A
Other languages
English (en)
Chinese (zh)
Inventor
S·勒克莱尔
J·恩德尔
S·哈特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphosys AG
Original Assignee
Morphosys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys AG filed Critical Morphosys AG
Publication of CN107614530A publication Critical patent/CN107614530A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
CN201680027238.0A 2015-05-13 2016-05-13 用于多发性骨髓瘤（mm）的治疗 Pending CN107614530A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15167597.2 2015-05-13
EP15167597 2015-05-13
PCT/EP2016/060810 WO2016180958A1 (en) 2015-05-13 2016-05-13 Treatment for multiple myeloma (mm)

Publications (1)

Publication Number Publication Date
CN107614530A true CN107614530A (zh) 2018-01-19

Family

ID=53174925

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680027238.0A Pending CN107614530A (zh) 2015-05-13 2016-05-13 用于多发性骨髓瘤（mm）的治疗

Country Status (24)

Country Link
US (2) US10533057B2 (https=)
EP (1) EP3294769B1 (https=)
JP (2) JP7160533B2 (https=)
KR (1) KR20180008571A (https=)
CN (1) CN107614530A (https=)
AU (1) AU2016260895B2 (https=)
CA (1) CA2984464C (https=)
CY (1) CY1123982T1 (https=)
DK (1) DK3294769T3 (https=)
ES (1) ES2862708T3 (https=)
HR (1) HRP20210552T1 (https=)
HU (1) HUE054271T2 (https=)
IL (1) IL255552B (https=)
LT (1) LT3294769T (https=)
MX (1) MX380557B (https=)
PL (1) PL3294769T3 (https=)
PT (1) PT3294769T (https=)
RS (1) RS61668B1 (https=)
RU (1) RU2723047C2 (https=)
SG (1) SG11201708691VA (https=)
SI (1) SI3294769T1 (https=)
SM (1) SMT202100202T1 (https=)
WO (1) WO2016180958A1 (https=)
ZA (1) ZA201708386B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109265551A (zh) * 2018-09-25 2019-01-25 华东师范大学 Cd38抗体、嵌合抗原受体和药物
CN114026121A (zh) * 2019-01-28 2022-02-08 赛诺菲 治疗多发性骨髓瘤的方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
PT3294769T (pt) * 2015-05-13 2021-04-13 Morphosys Ag Tratamento para mieloma múltiplo (mm)
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
KR20210006321A (ko) 2018-01-12 2021-01-18 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투여
CN110144008B (zh) * 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
BR112020019710A2 (pt) * 2018-03-28 2021-01-26 Takeda Pharmaceutical Company Limited métodos para tratar uma doença em um sujeito e para tratar um câncer hematológico em um sujeito, e, forma farmacêutica unitária.
CN113194925B (zh) * 2018-12-14 2025-03-07 莫佛塞斯公司 抗体制剂
US20200308296A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101218256A (zh) * 2005-03-23 2008-07-09 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
WO2012041800A1 (en) * 2010-09-27 2012-04-05 Morphosys Ag Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl
CN103421115A (zh) * 2013-09-02 2013-12-04 东南大学 一种cd38纳米抗体及应用
US20150118251A1 (en) * 2013-10-31 2015-04-30 Sanofi Specific anti-cd38 antibodies for treating human cancers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
WO1999062526A2 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
US8263746B2 (en) 2004-02-06 2012-09-11 Morphosys Ag Anti-CD38 human antibodies and uses thereof
DK2511297T3 (en) 2004-02-06 2015-06-15 Morphosys Ag Human anti-CD38 antibodies and their applications
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
EP2860192B1 (en) 2005-10-12 2017-09-27 MorphoSys AG Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
PL2068874T3 (pl) * 2006-08-07 2015-06-30 Abbvie Biotherapeutics Inc Sposoby leczenia szpiczaka mnogiego z użyciem terapii skojarzonych opartych na przeciwciałach anty-cs1
EP3569245A1 (en) * 2006-09-26 2019-11-20 Genmab A/S Combination treatment of cd38-expressing tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
DK2580243T3 (da) * 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
WO2014089279A1 (en) * 2012-12-05 2014-06-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rnf41 as a biomarker predicting response to lenalidomide in non-del(5q) mds
EP3834889A1 (en) 2014-06-16 2021-06-16 Mayo Foundation for Medical Education and Research Treating myelomas
US10617757B2 (en) * 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
MX386886B (es) 2014-09-09 2025-03-12 Janssen Biotech Inc Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias.
PT3294769T (pt) * 2015-05-13 2021-04-13 Morphosys Ag Tratamento para mieloma múltiplo (mm)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101218256A (zh) * 2005-03-23 2008-07-09 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
WO2012041800A1 (en) * 2010-09-27 2012-04-05 Morphosys Ag Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl
CN103421115A (zh) * 2013-09-02 2013-12-04 东南大学 一种cd38纳米抗体及应用
US20150118251A1 (en) * 2013-10-31 2015-04-30 Sanofi Specific anti-cd38 antibodies for treating human cancers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
F. HARTLEPP等: "MOR202 – a fully human antibody targeting CD38 for the treatment of multiple myeloma and other forms of blood-borne malignancies", 《EJC SUPPLEMENTS》 *
KATHARINA TEILUF等: "α-Radioimmunotherapy with 213Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma", 《ONCOTARGET》 *
NIH: "A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma", 《HISTORY OF CHANGES FOR STUDY: NCT01421186》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109265551A (zh) * 2018-09-25 2019-01-25 华东师范大学 Cd38抗体、嵌合抗原受体和药物
CN109265551B (zh) * 2018-09-25 2020-09-15 华东师范大学 Cd38抗体、嵌合抗原受体和药物
CN114026121A (zh) * 2019-01-28 2022-02-08 赛诺菲 治疗多发性骨髓瘤的方法

Also Published As

Publication number Publication date
AU2016260895B2 (en) 2021-08-05
IL255552B (en) 2022-01-01
US11591406B2 (en) 2023-02-28
ZA201708386B (en) 2019-06-26
DK3294769T3 (da) 2021-03-08
AU2016260895A1 (en) 2017-11-09
WO2016180958A1 (en) 2016-11-17
HRP20210552T1 (hr) 2021-05-14
KR20180008571A (ko) 2018-01-24
HUE054271T2 (hu) 2021-08-30
CY1123982T1 (el) 2022-05-27
PT3294769T (pt) 2021-04-13
CA2984464A1 (en) 2016-11-17
EP3294769B1 (en) 2021-01-13
IL255552A (en) 2018-01-31
US10533057B2 (en) 2020-01-14
JP7160533B2 (ja) 2022-10-25
US20190048091A1 (en) 2019-02-14
SI3294769T1 (sl) 2021-07-30
RU2017137496A3 (https=) 2019-06-13
RU2017137496A (ru) 2019-06-13
PL3294769T3 (pl) 2021-07-05
SG11201708691VA (en) 2017-11-29
RU2723047C2 (ru) 2020-06-08
LT3294769T (lt) 2021-04-26
JP2018515513A (ja) 2018-06-14
SMT202100202T1 (it) 2021-05-07
US20200079871A1 (en) 2020-03-12
ES2862708T3 (es) 2021-10-07
CA2984464C (en) 2023-10-10
RS61668B1 (sr) 2021-04-29
MX2017014396A (es) 2018-03-23
MX380557B (es) 2025-03-12
JP2021130668A (ja) 2021-09-09
EP3294769A1 (en) 2018-03-21

Similar Documents

Publication Publication Date Title
AU2018278327B2 (en) Activatable anti-pdl1 antibodies and methods of use thereof
US11591406B2 (en) Treatment for multiple myeloma (MM)
CN104684552B (zh) 组合及其用途
CN117222663A (zh) 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
US11795222B2 (en) Treatment of head and neck cancer
JP2024054123A (ja) 癌の治療のための配合剤
CN115151258A (zh) 使用pd-1拮抗剂、ilt4拮抗剂和乐伐替尼或盐的组合癌症治疗
EP3896089A1 (en) Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases
US20240010729A1 (en) Combination therapy of a pd-1 antagonist and lag3 antagonist and lenvatinib or a pharmaceutically acceptable salt thereof for treating patients with cancer
TW202547859A (zh) 抗人類pd-l1抗體及其用途
CN113993543B (zh) 使用抗cd38抗体的组合疗法
WO2024041652A1 (en) Methods of cancer treatment
HK1247939A1 (en) Treatment for multiple myeloma (mm)
WO2026021442A1 (zh) 抗体药物偶联物在制备治疗肺癌的药物中的用途
WO2025162364A1 (zh) 抗CD79b抗体药物偶联物联合免疫治疗剂、化疗剂治疗肿瘤
WO2025256641A1 (zh) 抗pd-l1抗体和抗ctla-4抗体联合治疗肿瘤
HK40051088A (en) Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases
EA047799B1 (ru) Лечение рака головы и шеи

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1247939

Country of ref document: HK